Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38

Patent 12129309 was granted and assigned to Xencor on October, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Xencor
Xencor
0
Date Filed
May 4, 2022
0
Date of Patent
October 29, 2024
0
Patent Applicant
Xencor
Xencor
0
Patent Application Number
17736475
0
Patent Citations
‌
US Patent 7276497 Cytotoxic agents comprising new maytansinoids
0
‌
US Patent 7303749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
0
‌
US Patent 7368565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
0
‌
US Patent 6884869 Pentapeptide compounds and uses related thereto
0
‌
US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof
0
‌
US Patent 7129261 Cytotoxic agents
0
‌
US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA
0
‌
US Patent 10259887 Heterodimeric antibodies that bind CD3 and tumor antigens
0
•••
Patent Inventor Names
Matthew Bernett
0
John Desjarlais
0
Gregory Moore
0
Umesh Muchhal
0
Rumana Rashid
0
Seung Chu
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12129309
0
Patent Primary Examiner
‌
Sean E Aeder
0
CPC Code
‌
C07K 16/40
0

Find more entities like US Patent 12129309 Heterodimeric antibodies that bind CD3 and CD38

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.